Nuclear Research Building
1280 Main Street West
Hamilton, Ontario, Canada, L8S 4K1
HAMILTON, ONTARIO, September 25, 2017 – Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced it has completed a second closing of its Series A financing, securing an additional $21 million USD in capital and bringing the total capital raised to $46 million USD. New investors in the second
CPDC’s Discovery Team is experienced in oncology, immuno-oncology, and neurology models.
CPDC and University Health Network have created a joint venture, CanProbe, to accelerate the clinical development of molecular imaging probes.
CPDC’s manufacturing facilities are approved by both Health Canada and the US FDA for the production of positron emitting radiopharmaceuticals.
Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.
During medical isotope shortages, CPDC can provide substitutes for use in bone scans and imaging kidney function.
CPDC can create PET and SPECT imaging companions for small molecules, peptides, antibodies and other biologics.
CPDC works with all therapeutic and diagnostic isotopes, and has extensive expertise with alpha and beta emitting nuclides.
Cyclotrons can be used to produce enough Tc-99m within 6 hours to enable over 500 nuclear imaging scans.
Molecular imaging probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.
ARTMS Products Inc. has been created by Triumf, BCCA, LHRI and CPDC to commercialize jointly-developed technology for production of Tc-99m on standard medical cyclotrons.